Fludarabine as a modulator of cisplatin activity in human in tumour primary cultures and established cell lines

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1766-1773

  Zaffaroni, N ^b   Orlandi, L ^a   Gornati, D ^b   De Marco, C ^b   Vaglini, M ^a   Silvestrini, R ^a  

^a Ist Naz Stud e la Cura dei Tumori   (Italy)

^b NONE

Author keywords

Cisplatin; Cytotoxicity; DNA repair; Fludarabine; Malanoma; Ovarian cancer

Indexed keywords

CISPLATIN; FLUDARABINE; FLUDARABINE PHOSPHATE;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL;

EID: 0030249296     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00176-1     Document Type: Article

References (39)

1. 1. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984, 100, 704-713.
2. 2. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985, 55, 2303-2316.
3. 3. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993, 71, 1571-1580.
4. 4. Eastman A. Characterization of the adduct produced in DNA by cis-diammine-dichloroplatinum and cis-dichloro (ethylene-diamine) platinum (II). Biochemistry 1983, 22, 3927-3933.
5. 5. Zhen W, Link CJ, O'Connor PM, et al. Increased gene specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992, 12, 3689-3698.
6. 6. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988, 48, 5713-5716.
7. 7. Swinnen LJ, Barnes DM, Fisher SG, Albain KS, Fisher RI, Erickson LC. 1-β-D-Arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum (II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res 1989, 49, 1383-1389.
8. 8. Frankfurt OS, Seckinger D, Sugarbaker EV. Inhibition of DNA repair in cells treated with a combination of alkylating agents. Anticancer Res 1993, 13, 947-952.
9. 9. Alaoui-Jamali M, Loubaba B-B, Robyn S, Tapiero H, Batist G. Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs. Cancer Chemother Pharmacol 1994, 34, 153-158.
10. 10. Floridi A, Paggi MG, Marcante ML. Lonidamine, a selective inhibitor of murine cancer cells. J Natl Cancer Inst 1981, 66, 497-499.
11. 11. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992, 52, 813-817.
12. 12. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989, 74, 19-25.
13. 13. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. J Biol Chem 1990, 265, 16617-16625.
14. 14. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL. In vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 1982, 21, 474-477.
15. 15. Parker VB, Bapat AR, Shen JX, Townsend AJ, Chen YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988, 34, 485-491.
16. 16. Catapano C, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-β-arabinofuranosyl-2-fluoroadenine 5′-triphosphate: a mechanism of DNA synthesis inhibition. J Biol Chem 1993, 268, 7179-7185.
17. 17. Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res 1991, 51, 1829-1835.
18. 18. Kamiya D, Huang P, Plunkett W. Mechanism of inhibition of the 3′→5′ exonuclease activity of human DNA polymerase by DNA containing fludarabine nucleotide. Proc Am Assoc Cancer Res 1994, 35, 393.
19. 19. Jayanth RV, Hittelmann WN. 9-β-D-arabinofuranosyl-2-fluroadenine (F-ara-A) inhibits both the fast and slow components of chromosome repair (Abstract). In Chapman JD, Dewey WC, Whitmore GF, eds. Radiation Research: A Twentieth Century Perspective. San Diego, Academic Press, 1991, 411.
20. 20. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995, 47, 1072-1079.
21. 21. Badaracco G, Corsi A, Maisto A, Natali PG, Starace G, Zupi G. Expression of tumor-associated antigens and kinetic profile of two melanoma cell lines. Cytometry 1981, 2, 63-69.
22. 22. Zupi G, Mauro F, Balduzzi MA, Pardini C, Cavaliere R, Greco C. Established melanoma cell lines from different metastatic nodules of a single patient. A useful model for cancer therapy. Proc Am Assoc Cancer Res 1985, 26, 22.
23. 23. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diammine-dichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987, 47, 414-118.
24. 24. Villa R, Zaffaroni N, Orlandi L, et al. Reliability of a primary culture system to test cytotoxic drug activity in human malignant melanoma. Int J Oncol 1992, 1, 619-624.
25. 25. Cordell JL, Falini B, Erber W, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32, 219-229.
26. 26. Yang LY, Li L, Keating MJ, Plunkett W. Fludarabine triphosphate inhibition of DNA excision repair of cisplatin-induced DNA adducts in a cell-free system. Proc Am Assoc Cancer Res 1994, 35, 396.
27. 27. Villa R, Zaffaroni N, Orlandi L, Bearzatto A, Costa A, Silvestrini R. In vitro effect of lonidamine on the cytotoxicity of mitomycin c and BCNU in human colon adenocarcinoma cells. Eur J Cancer 1994, 30A, 1534-1540.
28. 28. Tanigawa N, Kern DH, Hikasa Y, Morton DL. Rapid assay for evaluating the chemosensitivity of human tumors in soft-agar culture. Cancer Res 1982, 42, 2159-2164.
29. 3H-thymidine incorporation, to test drug sensitivity of human tumors. Int J Cell Cloning 1988, 6, 392-403.
30. 30. Kohn DW. DNA as a target in cancer chemotherapy: measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Meth Cancer Res 1979, 16, 291-298.
31. 31. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA. Measurement of strand breaks and cross-links by alkaline elution. In Freidberg EC, Hanawalt PC, eds. DNA Repair. A Laboratory Manual of Research Procedures. New York, Marcel Dekker, 1981, 379-401.
32. 32. Drewinko B, Loo TL, Brown B, Gottlib JA, Freireich EJ. Combination chemotherapy in vitro with adriamycin. Observation of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1976, 1, 187-195.
33. 33. Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995, 36, 181-188.
34. 34. Kish JA, Kopecky K, Samson MK, et al. Evaluation of fludarabine phosphate in malignant melanoma. Invest New Drugs 1991, 9, 105-108.
35. 35. Zwelling LA, Michaels S, Schwartz H, Dobson PO, Kohn KW. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res 1981, 41, 640-649.
36. 36. Zwelling LA, Kohn RW. Effects of cisplatin on DNA and the possible relationships to cytotoxicity and mutagenicity in mammalian cells. In Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin, Current Status and New Developments. New York, Academic Press Inc., 1980, 21-26.
37. 37. Balconi G, Broggini M, Erba E, et al. Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitro. Int J Cancer 1988, 41, 809-816.
38. 38. Zaffaroni N, Orlandi L, Villa R, Bearzatto A, Rofstad EK, Silvestrini R. DNA double-strand break repair and radiation response in human tumor primary cultures. Int J Radiat Biol 1994, 66, 279-285.
39. 39. Cheson BD. The purine analogs - A therapeutic beauty contest. J Clin Oncol 1992, 10, 352-355.